BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The X4 team will hold a fireside chat on February 12th at 12:30 p.m. ET and will be available for one-on-one meetings with investors. A webcast of the fireside chat will be available under the “Events ...

Core Viewpoint - X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The recent upgrade for X4 Pharmaceuticals reflects an improvement in its underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for X4 Pharmaceuticals has increased by 54.4%, indicating a strong upward trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns, particularly for Zacks Rank 1 stocks [7]. - X4 Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Wednesday [1] Group 2: Dynavax Technologies Corp - Shares of Dynavax Technologies Corp rose significantly after Sanofi SA announced its acquisition for $15.50 per share in cash, totaling an equity value of around $2.2 billion [1] - The acquisition enhances Sanofi's position in the adult immunization market [1] - Dynavax shares surged by 38.6% to close at $15.44 on Wednesday [1] Group 3: Other Notable Stock Movements - Omeros Corp shares increased by 66.8% to $14.60 following FDA approval of YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [3] - Edgewise Therapeutics Inc gained 23.8% to $26.94 after updates from the ongoing CIRRUS-HCM Phase 2 trial of EDG-7500 [3] - Agios Pharmaceuticals Inc shares surged by 17.9% to $29.00 after FDA approval of AQVESME for treating anemia in adults with thalassemia, priced at approximately $425,000 per patient per year [3] - Wheels Up Experience Inc saw a gain of 14.8% to $0.73 [3] - Travere Therapeutics Inc increased by 14.3% to $40.41 [3] - Coincheck Group NV shares rose by 12.5% to $2.88 [3] - Polestar Automotive Holding UK Plc jumped 11.8% to $16.92 after announcing a $300 million equity investment [3] - CapsoVision Inc gained 11.6% to $14.39 [3] - X4 Pharmaceuticals Inc increased by 9.5% to $4.52 [3] - Falcon's Beyond Global Inc shares rose by 9.4% to $18.35 following a $100 million mixed shelf offering [3] - BIOAGE Labs Inc jumped 8.8% to $14.37 [3] - Kodiak Sciences Inc gained 8.6% to $29.81 [3] - UiPath Inc increased by 7.9% to $17.23 after being announced as a replacement for Synovus Financial in the S&P MidCap 400 [3] - Immuneering Corp rose by 6.8% to $6.83, with an upcoming update on a clinical trial scheduled for January 7, 2026 [3] - Nike Inc shares gained 4.7% to $60.03 amid mixed investor sentiment regarding insider purchases and concerns over tariffs and demand in China [3] - Micron Technology Inc increased by 3.5% to $286.01 [3]

Group 1 - X4 Pharmaceuticals, Inc. (XFOR) has reached a key level of support, indicating a potential bullish breakout as its 50-day simple moving average has crossed above its 200-day simple moving average, forming a "golden cross" [1] - A golden cross signifies a trend reversal, starting from a downtrend, followed by the shorter moving average crossing above the longer moving average, and culminating in an upward price movement [2] - XFOR shares have increased by 8.4% over the past four weeks, and the company holds a 3 (Hold) rating on the Zacks Rank, suggesting a potential for further gains [3] Group 2 - There have been four upward revisions in earnings expectations for XFOR in the current quarter, with no downward revisions, indicating a positive sentiment among investors [3] - The Zacks Consensus Estimate for XFOR has also moved up, reinforcing the bullish outlook for the company [5]

Core Insights - X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on its primary asset, Mavorixafor, which is commercially branded as Xolremdi and approved in the US for WHIM syndrome [1] Company Overview - The company is in the process of expanding the use of Mavorixafor beyond its current approval for WHIM syndrome [1]

X4 Pharmaceuticals, Inc. ( XFOR ) is a biopharmaceutical firm built around its main asset, called Mavorixafor. The treatment is commercially branded as Xolremdi, and it's approved in the US for WHIM syndrome. It's also in the process of expanding toMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Busine ...

Summary of X4 Pharmaceuticals FY Conference Call Company Overview - **Company**: X4 Pharmaceuticals (NasdaqCM:XFOR) - **Focus**: Specializes in rare hematology diseases, particularly chronic neutropenia and WHIM syndrome [4][5] Key Points Management Transition - New management team joined X4 Pharmaceuticals three months prior, focusing on restructuring and financing [2] - Raised nearly $240 million to fund the phase 3 trial for chronic neutropenia [2] Lead Compound: Mavorixafor - **Indications**: Approved for WHIM syndrome, now targeting chronic neutropenia [9] - **Mechanism of Action**: Antagonizes CXCR4, facilitating the release of neutrophils from bone marrow into the bloodstream [7] - **Administration**: Oral agent, providing a competitive advantage over G-CSF, which requires injections and can cause discomfort [8] Market Opportunity - Estimated patient population for chronic neutropenia is approximately 15,000, significantly larger than the WHIM indication [5][12] - Current management of chronic neutropenia is inconsistent, with 40-45% of patients receiving G-CSF and 60% managed through other means [10][11] Clinical Trials - **Phase 2 Study**: Demonstrated that mavorixafor can increase ANC levels and can be safely combined with G-CSF [13][14] - **Phase 3 Study**: Double-blinded, placebo-controlled trial with 176 patients, focusing on ANC increase and reduction in infection rates [17][20] - Expected to complete enrollment by Q3 2026, with top-line data anticipated in the second half of 2027 [25] Competitive Landscape - Main competitor is G-CSF; no direct oral competitors currently exist [28] - Focus on generating combination data with G-CSF in the ongoing study [28] Commercialization Strategy - Plans to target a similar prescriber base as previous experiences with CTI and Bendeka [27] - Anticipates a premium pricing environment typical for rare diseases, though specific pricing strategies are still under development [27] Future Milestones - Completion of patient enrollment in the phase 3 trial is a critical upcoming milestone [29] - Ongoing efforts to better communicate market opportunities to investors [29] Collaborations - Strong relationship with Norjin for European rights, while focusing on the US market for commercialization [31] Additional Insights - The WHIM data collected from previous trials is being used to inform assumptions for the larger chronic neutropenia trial [9] - The company is restructuring to enhance trial enrollment efforts, particularly in the US [23][24]

Core Insights - X4 Pharmaceuticals will participate in the Guggenheim Second Annual Healthcare Innovation Conference from November 10-12, 2025, in Boston [1] - The management team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one meetings with investors [1] - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [2] Company Overview - X4 Pharmaceuticals focuses on developing and commercializing innovative therapies for patients with rare hematology diseases and significant unmet needs [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI for its first indication [3] - X4 is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with certain chronic neutropenic disorders [3]

Core Insights - X4 Pharmaceuticals reported a quarterly loss of $0.69 per share, better than the Zacks Consensus Estimate of a loss of $0.79, and a significant improvement from a loss of $5.41 per share a year ago, resulting in an earnings surprise of +12.66% [1] - The company generated revenues of $1.77 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 7.2%, but showing growth from $0.56 million in the same quarter last year [2] - X4 Pharmaceuticals shares have declined approximately 82% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for X4 Pharmaceuticals was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] - Current consensus EPS estimate for the next quarter is -$0.44 on revenues of $2.1 million, and for the current fiscal year, it is -$3.40 on revenues of $34.81 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which X4 Pharmaceuticals belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alvotech, another company in the same industry, is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year decline of 73.7%, with revenues projected at $128.22 million, up 24.5% from the previous year [9]

Financial Performance - Total revenue for Q3 2025 was $1.765 million, a significant increase from $560,000 in Q3 2024, representing a growth of 215% year-over-year[14] - Product revenue for the nine months ended September 30, 2025, reached $4.252 million, compared to $1.123 million for the same period in 2024, marking an increase of 278%[14] - For the nine months ended September 30, 2025, total revenue was $32.5 million, significantly up from $1.1 million in the same period of 2024, indicating a 2,841% increase[141] - The company reported net product revenue of $1.6 million for the three months ended September 30, 2025, an increase from $0.6 million in the same period of 2024, and total net revenue of $4.3 million for the nine months ended September 30, 2025, compared to $1.1 million for the same period in 2024[82] - For the three months ended September 30, 2025, the company recognized $1.8 million in revenue from external customers, compared to $0.6 million for the same period in 2024, representing a 196% increase[140] Net Loss and Expenses - The company reported a net loss of $29.815 million for Q3 2025, compared to a net loss of $36.696 million in Q3 2024, indicating an improvement of 18%[14] - For the nine months ended September 30, 2025, the company reported a net loss of $55.3 million, compared to a net income of $2.4 million for the same period in 2024[25] - The net loss for the three months ended September 30, 2025, was $29.8 million, compared to a net loss of $36.7 million for the same period in 2024, indicating an improvement of 18.9%[14] - Direct research and development expenses for the three months ended September 30, 2025, were $10.3 million, compared to $9.7 million in the same period of 2024, showing an increase of 6.4%[141] - Research and development expenses for Q3 2025 were $17.337 million, a decrease of 10% from $19.173 million in Q3 2024[14] Cash and Liquidity - Cash and cash equivalents increased to $69.632 million as of September 30, 2025, up from $55.699 million at the end of 2024, reflecting a growth of 25%[11] - As of September 30, 2025, total cash, cash equivalents, and restricted cash amounted to $70,435 thousand, an increase from $56,475 thousand as of December 31, 2024, representing a 24.5% increase[55] - The company reported a net cash used in operating activities of $70,091,000 for the nine months ended September 30, 2025, compared to $97,906,000 for the same period in 2024[25] - The company believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months[40] - As of September 30, 2025, the company had $122.2 million in cash, cash equivalents, and short-term marketable securities, with an accumulated deficit of $570.6 million[37] Assets and Liabilities - Total assets as of September 30, 2025, were $163.555 million, an increase of 12% from $146.447 million at the end of 2024[11] - Total liabilities decreased to $101.936 million as of September 30, 2025, down from $124.298 million at the end of 2024, representing a reduction of 18%[11] - The company’s accumulated deficit increased to $570.629 million as of September 30, 2025, compared to $515.355 million at the end of 2024[11] - The total stockholders' equity rose to $61.6 million as of September 30, 2025, compared to $22.1 million as of December 31, 2024, representing a substantial increase of 178.3%[11] Stock and Shareholder Information - The weighted average shares outstanding for basic net loss per share increased to 43,272,773 in Q3 2025, compared to 6,695,509 in Q3 2024[14] - The company executed a 1-for-30 reverse stock split on April 28, 2025, affecting all common stock share amounts retroactively[8] - The company excluded 15,633 potential shares of common stock from the computation of diluted net loss per share for the three months ended September 30, 2025, due to their anti-dilutive effect[70] - The company’s weighted average shares of common stock outstanding for the three months ended September 30, 2025, were 43,272,773 for both basic and diluted calculations[67] Clinical Development and Regulatory Status - The company is progressing in its pivotal Phase 3 clinical trial (the "4WARD" trial) for mavorixafor, with full enrollment expected in Q3 2026[28] - The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, a rare blood condition[28] - The company has one commercially approved product, XOLREMDI® (mavorixafor), for patients with WHIM syndrome[28] Strategic Restructuring - The company implemented a strategic restructuring in Q1 2025, resulting in a 30% reduction of its workforce, incurring charges of approximately $2.3 million for severance and related costs[74] - An additional strategic restructuring was announced on September 17, 2025, leading to a further workforce reduction of approximately 50%, with expenses of about $4.9 million for severance and related costs[75] Agreements and Contracts - The Company has entered into a license and supply agreement with Norgine Pharma UK Limited, which includes multiple performance obligations and various payment structures[46] - The company entered into a License and Supply Agreement with Norgine on January 13, 2025, receiving a one-time upfront payment of €28.5 million and a regulatory milestone payment of €0.5 million, with potential future payments totaling up to €225.6 million[79][80] Marketable Securities and Investments - The Company’s available-for-sale debt marketable securities as of September 30, 2025, had a fair value of $52.6 million[59] - The company incurred an unrealized loss on marketable securities of $10,000 for the three months ended June 30, 2025[25] Other Financial Metrics - The company recorded a change in fair value of warrant liability of $(12.8) million for the nine months ended September 30, 2025[25] - The fair value of the embedded derivative liability related to the Hercules Loan Agreement was estimated at $10 thousand as of September 30, 2025[60][62] - The Class C Warrant liability decreased from $13,755 thousand as of December 31, 2024, to $959 thousand as of September 30, 2025, reflecting a significant change in fair value[60][63]